CAPRA Blog

Welcome to the CAPRA Blog

Find an Article

Cost Recovery - Fees in Respect of Drugs and Medical Devices

Cost Recovery - Fees in Respect of Drugs and Medical Devices

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd. After two years of extensive engagement, new fees and policies will come into force April 1,...

Health Canada collaborates with U.S. and Australian regulators through Project Orbis: A framework for concurrent review of oncology products

Health Canada collaborates with U.S. and Australian regulators through Project Orbis: A framework for concurrent review of oncology products

Author:  Preetha Prabhu On Dec. 6, 2019, Health Canada issued a News Release titled “International collaboration among Canadian, U.S. and Australian regulators leads to...

Changes to the Cosmetic Ingredient Hotlist

Changes to the Cosmetic Ingredient Hotlist

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd. The Cosmetic Ingredient Hotlist is an administrative tool that Health Canada uses to...

Biosimilar Pharmaceuticals in Canada: Fact Sheet

Biosimilar Pharmaceuticals in Canada: Fact Sheet

Author: Bhavesh Patel This past August, Health Canada published a document titled “Biosimilar Biologic Drugs in Canada: Fact Sheet” to provide a comprehensive overview...

Health Canada Issues Important Safety Information for Ranitidine Products

Health Canada Issues Important Safety Information for Ranitidine Products

By: Pinky Mazumder On September 13, 2019 Health Canada issued an Important Safety Information to the general public titled “Health Canada assessing NDMA in ranitidine”....

Regulatory Enrolment Process (REP) Pilot for Clinical Trials

Regulatory Enrolment Process (REP) Pilot for Clinical Trials

Author: Bhavesh Patel Health Canada intends to launch a pilot project for clinical trial regulatory activities on November 1, 2019. The pilot project will be called the...

Health Canada: Drug and Medical Device Highlights 2018

Health Canada: Drug and Medical Device Highlights 2018

Author: Bhavesh Patel Health Canada published the report on drugs for human use, medical devices and drugs for veterinary use. The report sets out new drugs and medical...

Health Canada Notice on ICH Q3D (R1) the Guideline for Elemental Impurities

Health Canada Notice on ICH Q3D (R1) the Guideline for Elemental Impurities

By: Pinky Mazumder On May 31st, 2019, Health Canada issued a Notice titled the Release of the Finalised Guideline for ICH Q3D (R1): Guideline for Elemental Impurities and...

Special Access Program - Draft Guidance

Special Access Program - Draft Guidance

Author: Karen Zhou The Food and Drug Regulations (“FDR”) contains emergency provisions (Part C, Division 8, sections C.08.010 and C.08.011 of the FDR) to provide...

Improving Access to Clinical Data

Improving Access to Clinical Data

Author: Karen Zhou Health Canada has published final regulations that allow for the public release of clinical data on drugs and medical devices. Typically, clinical...

Health Canada’s Scanning and Consultations on What’s Next for Health Product Regulation

Health Canada’s Scanning and Consultations on What’s Next for Health Product Regulation

By: Pinky Mazumder With the rapid evolution of healthcare technologies, Health Canada undertook a scanning exercise to identify key drivers involved in shaping the future of...

Health Canada Getting Tougher on Opioid and Illegal Advertising

Health Canada Getting Tougher on Opioid and Illegal Advertising

Author: John Wong, Director, Regulatory Drug Advertising & Promotion, TPIReg/Inomar Strategies In light of the on-going and escalating opioid crisis, the Federal Health...